Fidelity International’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Fidelity International’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-75,446	Closed	-$4.43M	–	908
2023 Q4	$4.43M	Buy	75,446 +6,062	+9%	+$341K	﹤0.01%	589
2023 Q3	$3.02M	Buy	69,384 +15,950	+30%	+$569K	﹤0.01%	601
2023 Q2	$1.93M	Buy	+53,434	New	+$2.2M	﹤0.01%	642
2020 Q1	–	Sell	-65	Closed	-$8K	–	1039
2019 Q4	$8K	Buy	+65	New	+$6.27K	﹤0.01%	757
2019 Q2	–	Sell	-57,065	Closed	-$4.18M	–	994
2019 Q1	$4.18M	Buy	+57,065	New	+$3.88M	0.01%	525

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fidelity International's MRTX Position: Q1 2024 in Review

Fidelity International sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 75,446 shares — an estimated $4.43M sold.

Fidelity International first reported a position in MRTX in Q1 2019 and held it in 5 quarters. The position peaked at $4.43M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Fidelity International reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Fidelity International sold 75,446 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $4.43M.
Fidelity International first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and held it in 5 quarters.
Fidelity International's Mirati Therapeutics, Inc. Common Stock position peaked at $4.43M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Fidelity International's 13F filing for Q1 2024, filed 13 May 2024.